Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.

Study summary

The purpose of this protocol is to obtain biologic materials from the mediastinal lymph nodes from patients with lung disease and mediastinal lymph node involvement in order to: (1) develop a better understanding of the cause and development of lung disorders involving the mediastinal lymph nodes; (2) identify biologic parameters that help diagnose and predict the behavior of human lung diseases; and (3) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Disease · Inflammation

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 26, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Weill Medical College of Cornell University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Weill Medical College of Cornell University
Interventions being studied: Not specified

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Must provide informed consent
Males and females, age 18 years and older
Lung disease proven by at least one of the following: 1. symptoms consistent with pulmonary disease 2. chest X-ray and chest CT and/or PET CT scan consistent with lung disease and mediastinal lymph node involvement 3. lung biopsy consistent with lung disease known to involve mediastinal lymph nodes 4. patients with diseases of organs with known association to lung disease and mediastinal lymph node involvement.
Undergoing fiberoptic bronchoscopy with EBUS-TBNA as dictated by their standard clinical care

Reasons someone may not be able to joinExclusion criteria

Patient refuses consent.
Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, or any local anesthetic will not be included in the study
Individuals who cannot tolerate general anesthesia or moderate sedation and analgesia

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic MedicineNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 26, 2017. Always confirm current availability with the study team.

View original record ↗